EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
EyePoint, Inc. reports Q2 2026 financial results highlighting progress in its DURAVYU pivotal Phase 3 trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data for wet AMD trials LUGANO and LUCIA are expected in August 2026 and Q4 2026 respectively, while pivotal DME trials COMO and CAPRI are fully enr…